Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 108 peer-reviewed journal articles Updated

Multinodular Goiter: A Patient Guide

At a Glance

Multinodular goiter usually causes an enlarged thyroid with several noncancerous nodules. Doctors use hormone blood tests, ultrasound, and selective biopsy to guide monitoring or treatment such as radioactive iodine, ablation, medication, or surgery.

A diagnosis of multinodular goiter means your thyroid gland has become enlarged and contains several distinct lumps or nodules [1]. While finding multiple growths in your neck can be alarming, it is important to know that this is a common condition that is overwhelmingly benign (non-cancerous) [2]. In fact, having many nodules does not automatically multiply your risk of cancer; population-level research often shows that the risk for a person with multiple nodules is similar to the risk for someone with just one [3][4]. Each clinically relevant nodule is carefully assessed by your doctor based on its ultrasound pattern, your clinical history, and whether it is growing [5].

Your medical team will first determine if your goiter is nontoxic or toxic. A nontoxic multinodular goiter is the most common type, where the thyroid is enlarged but your hormone levels generally remain normal and it is not causing thyrotoxicosis [6]. In contrast, a toxic multinodular goiter occurs when certain nodules begin to produce extra thyroid hormone on their own, leading to an overactive thyroid (hyperthyroidism) [7]. This distinction is vital because it guides every step of your care, from the types of blood tests you need to the choice of treatment [8][1].

Evaluating a multinodular goiter is a selective process. Instead of biopsying every single nodule, doctors use high-resolution ultrasound to look for specific “suspicious” features, such as irregular edges or tiny calcium spots [9][5]. By combining these visual clues with the size of the nodules and your medical history, your doctor can target only the ones that truly require a fine-needle aspiration (FNA) biopsy [10][11]. This targeted approach helps prevent unnecessary procedures while ensuring that any potentially concerning growths are carefully examined [12].

If a biopsy result is “indeterminate”—meaning the cells do not look clearly benign but aren’t clearly cancerous—molecular testing can sometimes provide a clearer answer [13]. These advanced tests analyze the DNA and RNA within the thyroid cells to substantially reduce the estimated risk of cancer, although they do not guarantee zero risk [14][15]. A negative molecular test often means you and your doctor can confidently choose active surveillance, where the goiter is monitored with regular ultrasounds [16][17]. However, very large or compressive nodules may still require surgery regardless of the test result [18].

Treatment for multinodular goiter is highly personalized and based on your symptoms and the goiter’s behavior. For many, monitoring is all that is required. If treatment is needed due to size or hormone issues, options include radioactive iodine (RAI) to slowly shrink the gland, radiofrequency ablation (RFA) to safely treat specific bothersome nodules using heat, or temporary use of medications to control hormone levels [19][20]. Surgery remains an effective option for very large goiters, cases where cancer is suspected, or when conservative options are not suitable [21][18]. Your journey with a multinodular goiter is about finding the right balance between careful monitoring and active management to protect your health and comfort [8].

In this guide

6 chapters

01

Understanding Your Diagnosis: Multinodular Goiter

Learn what multinodular goiter means, how toxic and nontoxic types differ, and how TSH tests, ultrasound, scans, and biopsies guide evaluation and monitoring.

02

Symptoms, Progression, and Warning Signs

Learn which multinodular goiter symptoms are routine, when swallowing or hoarseness needs prompt care, and which breathing changes require emergency help.

03

Blood Tests, Ultrasound, and Risk Assessment

Learn how multinodular goiter is evaluated with TSH tests, ultrasound risk scores, radioactive iodine scans, and selective biopsy decisions for each nodule.

04

The Thyroid Biopsy and the Bethesda System

Learn what multinodular goiter biopsy results mean, including Bethesda categories, molecular testing, repeat FNA, and when surgery or monitoring may follow.

05

Treatment Options: From Monitoring to Surgery

Learn about multinodular goiter treatment, including monitoring, radioactive iodine, radiofrequency ablation, thyroid surgery, benefits, risks, and follow-up.

06

Navigating Large and Substernal Goiters

Learn how CT, laryngoscopy, and specialist surgery guide care for large substernal multinodular goiters, including airway, nerve, and chest surgery risks.

Common questions in this guide

What is multinodular goiter, and does it mean I have thyroid cancer?
Multinodular goiter means the thyroid gland is enlarged and contains several nodules. Most multinodular goiters are benign, and having multiple nodules does not automatically mean the cancer risk is higher than with one nodule. Doctors assess each important nodule using ultrasound, medical history, and changes over time.
Why do some thyroid nodules need a biopsy while others do not?
Ultrasound helps doctors look for features that may be concerning, such as irregular edges or tiny calcium deposits. Nodule size, ultrasound appearance, growth, and your medical history help determine which nodules need a fine-needle aspiration biopsy. This targeted approach avoids unnecessary biopsies while evaluating nodules that need closer attention.
What is the difference between a toxic and nontoxic multinodular goiter?
A nontoxic multinodular goiter is enlarged but generally does not produce excess thyroid hormone. A toxic multinodular goiter contains nodules that make extra hormone, which can cause an overactive thyroid. The distinction affects blood testing, monitoring, and treatment choices.
What happens if my thyroid biopsy result is indeterminate?
An indeterminate result means the cells do not clearly look benign or cancerous. Molecular testing can examine the cells' DNA and RNA and may lower the estimated risk of cancer, but it cannot guarantee that cancer is absent. Very large or compressive nodules may still require surgery even when molecular testing is reassuring.
Do all multinodular goiters need treatment?
No. Many multinodular goiters can be monitored with follow-up visits and ultrasound, especially when they cause no significant symptoms or hormone problems. Treatment may be considered for bothersome or compressive nodules, excess thyroid hormone, substantial growth, or concern about cancer.
What treatments are available for multinodular goiter?
Depending on the goiter's size, symptoms, hormone activity, and test results, options may include active surveillance, radioactive iodine, radiofrequency ablation, medication to control thyroid hormone levels, or surgery. Your clinician can compare the benefits and risks of each option for your specific situation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my TSH levels and ultrasound findings, which of my nodules are considered 'dominant' and which are 'suspicious'?
  2. 2.If my biopsy result comes back as 'indeterminate,' will we use molecular testing to help decide if surgery is necessary?
  3. 3.For my specific goiter, what are the pros and cons of active surveillance versus more active treatments like RFA or surgery?
  4. 4.If I have a 'toxic' goiter, how will that change our approach to biopsy and long-term monitoring?
  5. 5.How often will I need ultrasound imaging to monitor for any changes in the size or appearance of my nodules?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Non-Toxic Multinodular Goiter: From Etiopathogenesis to Treatment.

    Unlu MT, Kostek M, Aygun N, et al.

    Sisli Etfal Hastanesi tip bulteni 2022; (56(1)):21-40 doi:10.14744/SEMB.2022.56514.

    PMID: 35515961
  2. 2

    Should the Prevalence of Incidental Thyroid Cancer Determine the Extent of Surgery in Multinodular Goiter?

    Kaliszewski K, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, et al.

    PloS one 2016; (11(12)):e0168654 doi:10.1371/journal.pone.0168654.

    PMID: 28005977
  3. 3

    Solitary and multiple thyroid nodules as predictors of malignancy: a systematic review and meta-analysis.

    Rehman AU, Ehsan M, Javed H, et al.

    Thyroid research 2022; (15(1)):22 doi:10.1186/s13044-022-00140-6.

    PMID: 36464691
  4. 4

    Patient outcomes following surgical management of multinodular goiter: Does multinodularity increase the risk of thyroid malignancy?

    Lin YS, Wu HY, Yu MC, et al.

    Medicine 2016; (95(28)):e4194 doi:10.1097/MD.0000000000004194.

    PMID: 27428220
  5. 5

    Cancer Risk in Thyroid Nodules: An Analysis of Over 1000 Consecutive FNA Biopsies Performed in a Single Canadian Institution.

    Smit EJ, Samadi S, Wilson MP, Low G

    Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242775.

    PMID: 39767136
  6. 6

    Hyperthyroidism.

    Chaker L, Cooper DS, Walsh JP, Peeters RP

    Lancet (London, England) 2024; (403(10428)):768-780 doi:10.1016/S0140-6736(23)02016-0.

    PMID: 38278171
  7. 7

    The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism.

    Mariani G, Tonacchera M, Grosso M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021; (62(3)):304-312 doi:10.2967/jnumed.120.243170.

    PMID: 33008929
  8. 8

    Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters.

    Knobel M

    Journal of endocrinological investigation 2016; (39(4)):357-73 doi:10.1007/s40618-015-0391-7.

    PMID: 26392367
  9. 9

    AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE.

    Gharib H, Papini E, Garber JR, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2016; (22(5)):622-39 doi:10.4158/EP161208.GL.

    PMID: 27167915
  10. 10

    2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

    Haugen BR, Alexander EK, Bible KC, et al.

    Thyroid : official journal of the American Thyroid Association 2016; (26(1)):1-133 doi:10.1089/thy.2015.0020.

    PMID: 26462967
  11. 11

    Use of the thyroid imaging, reporting, and data system (TI-RADS) scoring system for the evaluation of subcentimeter thyroid nodules.

    Weiss VL, Andreotti RF, Ely KA

    Cancer cytopathology 2018; (126(8)):518-524 doi:10.1002/cncy.22015.

    PMID: 29733503
  12. 12

    The Diagnosis and Management of Thyroid Nodules: A Review.

    Durante C, Grani G, Lamartina L, et al.

    JAMA 2018; (319(9)):914-924 doi:10.1001/jama.2018.0898.

    PMID: 29509871
  13. 13

    The 2023 Bethesda System for Reporting Thyroid Cytopathology.

    Ali SZ, Baloch ZW, Cochand-Priollet B, et al.

    Thyroid : official journal of the American Thyroid Association 2023; (33(9)):1039-1044 doi:10.1089/thy.2023.0141.

    PMID: 37427847
  14. 14

    Comparing the diagnostic accuracy of Afirma GSC to ThyroSeq V3 in cytologically indeterminate thyroid nodules.

    Dowell N, Begum S, Muzaffar J, et al.

    European thyroid journal 2025; (14(6)).

    PMID: 41324437
  15. 15

    Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.

    Steward DL, Carty SE, Sippel RS, et al.

    JAMA oncology 2019; (5(2)):204-212 doi:10.1001/jamaoncol.2018.4616.

    PMID: 30419129
  16. 16

    Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.

    Livhits MJ, Zhu CY, Kuo EJ, et al.

    JAMA oncology 2021; (7(1)):70-77 doi:10.1001/jamaoncol.2020.5935.

    PMID: 33300952
  17. 17

    Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.

    Kim NE, Raghunathan RS, Hughes EG, et al.

    The Journal of clinical endocrinology and metabolism 2023; (108(9)):e698-e703 doi:10.1210/clinem/dgad181.

    PMID: 36995878
  18. 18

    Current approach to surgical management of hyperthyroidism.

    Barczyński M

    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 2021; (65(2)):124-131 doi:10.23736/S1824-4785.21.03330-6.

    PMID: 33494587
  19. 19

    Fixed 30 mCi 131I-iodine therapy without recombinant human thyroid-stimulating hormone stimulation as an attractive therapeutic alternative in nontoxic nodular goiter.

    Riguetto CM, Miguel VP, Pavin EJ, et al.

    Nuclear medicine communications 2020; (41(8)):727-732 doi:10.1097/MNM.0000000000001213.

    PMID: 32427701
  20. 20

    2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules.

    Papini E, Monpeyssen H, Frasoldati A, Hegedüs L

    European thyroid journal 2020; (9(4)):172-185 doi:10.1159/000508484.

    PMID: 32903999
  21. 21

    Substernal Goiter: From Definitions to Treatment.

    Unlu MT, Aygun N, Kostek M, et al.

    Sisli Etfal Hastanesi tip bulteni 2022; (56(2)):167-176 doi:10.14744/SEMB.2022.30806.

    PMID: 35990303

This page is for informational purposes only and does not constitute medical advice. Your clinician should interpret your thyroid tests and imaging and discuss the safest monitoring or treatment plan for your situation.

Get notified when new evidence is published on multinodular goiter.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.